<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombopoietin (TPO) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> represent a new approach for the treatment of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, which may develop as a consequence of <z:hpo ids='HP_0001973'>immune thrombocytopenia</z:hpo>, chemotherapy treatment, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>There are concerns that use of certain growth factors can hasten disease progression in some types of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, expression of MPL (TPO-R) <z:chebi fb="2" ids="33699">mRNA</z:chebi> was examined in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples (<z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo>, prostatic <z:mp ids='MP_0002038'>carcinoma</z:mp>, soft tissue and bony/cartilage <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, and <z:hpo ids='HP_0002665'>lymphoma</z:hpo>), and <z:mpath ids='MPATH_458'>normal</z:mpath> tissues using microarray analysis and qRT-PCR </plain></SENT>
<SENT sid="3" pm="."><plain>MPL <z:chebi fb="2" ids="33699">mRNA</z:chebi> is expressed at very low or undetectable levels compared with erythropoietin receptor (EPOR), human epidermal growth factor (ERBB2; HER2), and insulin-like growth factor-1 receptor (IGF1R) in these patient samples </plain></SENT>
<SENT sid="4" pm="."><plain>These data suggest TPO-R <z:chebi fb="4" ids="48705">agonists</z:chebi> will likely preferentially stimulate proliferation and differentiation of cells of megakaryocytic lineage, potentially demonstrating their utility for correcting <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in clinical settings </plain></SENT>
</text></document>